The Alpha-1 Foundation is a not-for-profit Florida corporation founded in 1995 by John Walsh, Sandy Lindsey and Susan Stanley, three individuals diagnosed with Alpha-1 Antitrypsin Deficiency (Alpha-1). A majority of the Board of Directors is either diagnosed with Alpha-1 or has a family member diagnosed with Alpha-1.
The Alpha-1 Foundation has invested nearly $47 million to support Alpha-1 Antitrypsin research & programs in almost 90 institutions worldwide. They offer two distinct types of financial support: Peer reviewed grants program; and Investment funding for translational research through The Alpha-1 Project, all of which include work with stem cells.
The Foundation has developed a solid infrastructure to promote research and the development of new therapies for improving the quality of life for those diagnosed with Alpha-1. It has fostered collaborations with investigators throughout the United States and Europe, working closely with the National Institutes of Health (NIH), the Food and Drug Administration (FDA), individuals affected by Alpha-1, and the pharmaceutical industry to expedite the development of improved therapies.
The Foundation participates in industry and government liaison groups and develops strategic alliances with government, industry and other national and international health and research organizations.